Get the Stockscreener App
1.37
5.38%
0.07
AIM ImmunoTech Inc stock is traded at $1.37, with a volume of 22,042.
It is up +5.38% in the last 24 hours and down -47.51% over the past month.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$1.30
Open:
$1.29
24h Volume:
22,042
Relative Volume:
0.23
Market Cap:
$3.91M
Revenue:
$202.00K
Net Income/Loss:
$-28.96M
P/E Ratio:
-2.2833
EPS:
-0.6
Net Cash Flow:
$-21.85M
1W Performance:
-2.84%
1M Performance:
-47.51%
6M Performance:
+1,344%
1Y Performance:
+547.14%
1-Day Range:
$1.26
$1.37
1-Week Range:
$1.26
$1.4598
52-Week Range:
$0.0633
$20.35
AIM ImmunoTech Inc Stock (AIM) Company Profile
Name
AIM ImmunoTech Inc
Sector
Industry
Phone
352 448 7797
Address
2117 SW Highway 484, Ocala, FL
Compare AIM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
1.37 | 3.59M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
AIM ImmunoTech Inc Stock (AIM) Latest News
What analyst consensus implies for AIM ImmunoTech Inc. (HXB) stock2025 Fundamental Recap & Daily Volume Surge Trade Alerts - newser.com
Why global investors buy AIM ImmunoTech Inc. stockWeekly Stock Report & Daily Oversold Bounce Ideas - newser.com
Why AIM ImmunoTech Inc. stock fits value portfoliosJuly 2025 Levels & Community Trade Idea Sharing Platform - newser.com
Will AIM ImmunoTech Inc. (HXB) stock deliver stable dividends2025 Technical Overview & Risk Adjusted Buy/Sell Alerts - newser.com
How AIM ImmunoTech Inc. (HXB) stock behaves under inflation pressureMarket Movers & Real-Time Chart Breakout Alerts - newser.com
Is AIM ImmunoTech Inc. (HXB) stock vulnerable to rate hikesQuarterly Portfolio Report & Safe Capital Growth Tips - newser.com
Can AIM ImmunoTech Inc. stock deliver strong annual returnsJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - newser.com
Is AIM ImmunoTech Inc. stock a buy on weaknessJuly 2025 Movers & Real-Time Volume Analysis - newser.com
Can AIM ImmunoTech Inc. (HXB) stock resist broad market declines2025 Market Outlook & Technical Pattern Alert System - newser.com
Is AIM ImmunoTech Inc. (HXB) stock bottoming after sell offGDP Growth & Step-by-Step Trade Execution Guides - newser.com
AIM ImmunoTech Enters Note Purchase Agreement - TipRanks
Aim ImmunoTech enters Note Purchase Agreement with Streeterville Capital, says SEC filing - MarketScreener
Is AIM ImmunoTech Inc. stock a buy before new product rollout2025 Price Targets & Precise Trade Entry Recommendations - newser.com
Is AIM ImmunoTech Inc. (HXB) stock resilient in recession scenariosJuly 2025 Volume & Trade Opportunity Analysis Reports - newser.com
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program - The Manila Times
AIM ImmunoTech reports third quarter 2025 financial results and highlights continued progress across pipeline with strategic focus on pancreatic cancer clinical program - MarketScreener
AIM ImmunoTech (NYSE American: AIM) Q3 2025 highlights pancreatic cancer Ampligen program, $2.4M cash - Stock Titan
AIM ImmunoTech Reports Q3 2025 Financial Results - TipRanks
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Can AIM ImmunoTech Inc. stock expand revenue streamsWeekly Stock Analysis & Capital Efficiency Focused Ideas - newser.com
AIM ImmunoTech Inc Stock (AIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):